Keystone Nano can target NanoJackets and NanoLiposomes passively or actively to deliver drugs to solid and non-solid tumors. Polyethylene glycol (PEG) conjugated NanoJackets and NanoLiposomes demonstrate increased circulation times and accumulate in tumors through enhanced permeability and retention to treat non-solid tumors. We have achieved active targeting by further conjugating target-specific peptides to NanoJacket surfaces.

NanoJackets encapsulating various chemotherapeutics have been tested in animal models of breast and pancreatic cancers, while our NanoLiposomes have been tested in in vivo models of melanoma, breast cancer, liver cancer and leukemia. During testing in in vivo models of leukemias, our NanoJackets and NanoLiposomes have demonstrated significantly enhanced efficacy in comparison with free compounds. All studies to date have supported the lack of toxicity and enhanced efficacy of NanoJacket and NanoLiposome encapsulated drugs. Data demonstrating in vivo efficacy of NanoJackets and NanoLiposomes can be found in peer-reviewed publications.